US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

26.34

+0.47001.82%

Post-market: 26.340.00000.00%16:20 EDT

Volume:226.52K

Turnover:5.88M

Market Cap:741.37M

PE:-11.26

High:26.44

Open:26.34

Low:24.86

Close:25.87

Loading ...

Overview Company News Filings

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Aerovate Therapeutics Inc trading halted, news pending

D.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments

MT Newswires Live

Vesicor Therapeutics to Go Public Via SPAC

Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025

Press Release: Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles

Press Release: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Foghorn Therapeutics announces new preclinical data at AACR

BriaCell Therapeutics Closes $13.8 Million Public Offering

Spero Therapeutics Appoints New CEO Esther Rajavelu

Foghorn Therapeutics Presents Preclinical Data at AACR 2025

ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Press Release: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment

MT Newswires Live

Relmada Therapeutics Announces Positive Phase 2 Study Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":26.34,"timestamp":1746820800000,"preClose":25.87,"halted":0,"volume":226520,"hourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"delay":0,"floatShares":11456571,"shares":28146154,"eps":-2.338654,"marketStatus":"Market Closed","change":0.47,"latestTime":"05-09 16:00:00 EDT","open":26.34,"high":26.44,"low":24.86,"amount":5880456.606978,"amplitude":0.061075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.338654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":25.87,"preHourTrading":{"tag":"盘前","latestPrice":26.3,"preClose":25.87,"latestTime":"09:29 EDT","volume":321,"amount":8435.569914,"timestamp":1746797398443},"postHourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"volumeRatio":0.8674420486669012,"impliedVol":0.6531,"impliedVolPercentile":0.8182},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11456571,"roa":"-17.75%","roe":"-24.47%","lyrEps":-2.338654,"volumeRatio":0.8674420486669012,"shares":28146154,"dividePrice":0,"high":26.44,"amplitude":0.061075,"preClose":25.87,"low":24.86,"week52Low":14.42,"pbRate":"3.86","week52High":38.93,"institutionHeld":0,"latestPrice":26.34,"eps":-2.338654,"divideRate":0,"volume":226520,"delay":0,"ttmEps":-2.338654,"open":26.34,"prevYearClose":28.87,"prevWeekClose":29.52,"prevMonthClose":28.515,"prevQuarterClose":25.71,"fiveDayClose":29.52,"twentyDayClose":18.54,"sixtyDayClose":24.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531920241","title":"Serina Therapeutics to Present at JonesResearch Virtual CNS Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2531920241","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531920241?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:00","pubTimestamp":1745920800,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, April 29, 2025  -- Serina Therapeutics, Inc.  , a clinical-stage biotechnology company developing its proprietary POZ Platformdrug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTMprovides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates . Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/serina-therapeutics-present-jonesresearch-virtual-100000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","LENZ","BK4007","BK4135","BK4139","SER"],"gpt_icon":0},{"id":"2531291572","title":"Aerovate Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291572?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:50","pubTimestamp":1745884207,"startTime":"0","endTime":"0","summary":"19:50 EDT Aerovate Therapeutics (AVTE) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aerovate-therapeutics-inc-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aerovate-therapeutics-inc-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVTE","JBIO","LENZ","BK4539","BK4007"],"gpt_icon":0},{"id":"2531574299","title":"D.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2531574299","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531574299?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:41","pubTimestamp":1745883668,"startTime":"0","endTime":"0","summary":"D. Western Therapeutics Institute  has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.Price : $108.00, Change: $+2.0, Percent Change: +1.89%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","JPY","BK4007"],"gpt_icon":0},{"id":"2531298710","title":"Vesicor Therapeutics to Go Public Via SPAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298710","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298710?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:33","pubTimestamp":1745879580,"startTime":"0","endTime":"0","summary":"Vesicor Therapeutics has signed a deal to combine with special purpose acquisition company Black Hawk Acquisition.The blank-check company said Monday that it has reached a business-combination agreement with Vesicor, a California biotechnology company.Vesicor was founded in 2008 and focuses on the development of p53-based cancer therapeutics delivered through microvesicles.The transaction, which has been approved by the boards of both companies, gives Vesicor a pre-money equity value of $70 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKHA","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2531672202","title":"Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531672202","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531672202?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:47","pubTimestamp":1745876832,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics ( ($TSE:CRDL) ) has provided an update. Cardiol Therapeutics Inc. has announced its upcoming annual general meeting of shareho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-schedules-virtual-annual-general-meeting-for-may-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-schedules-virtual-annual-general-meeting-for-may-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2531426237","title":"Press Release: Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles","url":"https://stock-news.laohu8.com/highlight/detail?id=2531426237","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531426237?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:30","pubTimestamp":1745875800,"startTime":"0","endTime":"0","summary":"Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles. -- Transaction Values Vesicor at a Pre-money Equity Value of $70 million. -- Business Combination is Expected to be Completed in the Fourth Quarter of. DANVILLE, Calif., April 28, 2025  -- Black Hawk Acquisition Corp. , a special purpose acquisition company,  announced the signing of a Business Combination Agreement  on April 26, 2025, with Vesicor Therapeutics, Inc. , a California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles.Vesicor was founded in 2008 in San Gabriel, California by Luo Feng, Ph.D. The Company is an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered micr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BKHAU","BK4139","LENZ"],"gpt_icon":0},{"id":"2531394269","title":"Press Release: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531394269","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531394269?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:53","pubTimestamp":1745873580,"startTime":"0","endTime":"0","summary":"TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting. WALTHAM, Mass., April 28, 2025  -- TScan Therapeutics, Inc. , a clinical-stage biotechnology company focused on the development of T cell receptor -engineered T cell  therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy  28  Annual Meeting being held May 13 -- 17 in New Orleans, LA as well as virtually.Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation. A copy of the presentation materials will be added to the \"Publications\" section of the Company's website at tscan.com once the presentation has concluded.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4107","BK4099","BK4555","BK4588","BK4117","TCRX","AFG","BK4585","03160","BK4604","TM","BK4007"],"gpt_icon":0},{"id":"2531926947","title":"Foghorn Therapeutics announces new preclinical data at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2531926947","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531926947?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:45","pubTimestamp":1745873106,"startTime":"0","endTime":"0","summary":"Foghorn Therapeutics (FHTX) announced new preclinical data for medicines, including FHD-909, a SMARCA2 selective inhibitor, and the Selective CBP d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/foghorn-therapeutics-announces-new-preclinical-data-at-aacr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/foghorn-therapeutics-announces-new-preclinical-data-at-aacr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","FHTX","BK4139"],"gpt_icon":0},{"id":"2531266324","title":"BriaCell Therapeutics Closes $13.8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266324","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266324?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:39","pubTimestamp":1745872746,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. BriaCell Therapeutics has successfully closed a public offering, raising approximatel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-closes-13-8-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-closes-13-8-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2531266880","title":"Spero Therapeutics Appoints New CEO Esther Rajavelu","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266880","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266880?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:36","pubTimestamp":1745872606,"startTime":"0","endTime":"0","summary":"Spero Therapeutics ( ($SPRO) ) has shared an announcement. On April 28, 2025, Spero Therapeutics announced the appointment of Esther Rajavelu as Pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spero-therapeutics-appoints-new-ceo-esther-rajavelu?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spero-therapeutics-appoints-new-ceo-esther-rajavelu?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2531265066","title":"Foghorn Therapeutics Presents Preclinical Data at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531265066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531265066?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:32","pubTimestamp":1745872356,"startTime":"0","endTime":"0","summary":"Foghorn Therapeutics ( ($FHTX) ) just unveiled an announcement. On April 28, 2025, Foghorn Therapeutics announced preclinical data for several prog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/foghorn-therapeutics-presents-preclinical-data-at-aacr-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/foghorn-therapeutics-presents-preclinical-data-at-aacr-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","FHTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2531266328","title":"ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266328","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266328?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:31","pubTimestamp":1745872269,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a le...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-assumed-with-an-overweight-at-cantor-fitzgerald?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-assumed-with-an-overweight-at-cantor-fitzgerald?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2531392260","title":"Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392260","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531392260?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:31","pubTimestamp":1745872260,"startTime":"0","endTime":"0","summary":"One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models. \"We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,\" said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. \"We are particularly excited to be presenting, in the prestigious Presidential Symposium, our potent combination of epigenetic regulation and capsid delivery capabilities as an anticipated one-time intravenous treatment for prion disease. It will be an honor to highlight the groundbreaking potential of our work and the dedication of our teams in advancing treatment options for neurology patients in need.\". Additional poster presentations at the ASGCT Annual Meeting will showcase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-present-neurology-pipeline-203100252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","AFG","BK4135","CNS","SGMO","BK4139","BK4007","BK4550","MINT","BK4117","BK4585","LENZ","BK4556","BK4107"],"gpt_icon":0},{"id":"2531608266","title":"Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531608266","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531608266?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 28, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company’s Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-appoints-timothy-watkins-200500814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","LU1066053197.SGD","LU1585245621.USD","CTNM","LU1571399168.USD","BK4568","USJW.SI","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0234570918.USD","BK4139","USAW.SI","LU1066051498.USD","QLD","BK4585","NVIW.SI","LU0109394709.USD","LU0320765992.SGD","LU2087621335.USD","SQQQ","BK4588","PSQ","TSYW.SI","NQmain","QID","MNQmain","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","GILD","LENZ","IE00BKVL7J92.USD","LU2468319806.SGD","LU0289739699.SGD","TQQQ","BK4578","IE00B19Z3581.USD","IE0002270589.USD","BK4566","BK4007","BK4583","IE00B3T34201.USD","LU2089984988.USD","LU0058720904.USD","BK4550","LU1839511570.USD",".IXIC","LU0889565916.HKD","BK4532"],"gpt_icon":1},{"id":"2531269036","title":"Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2531269036","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531269036?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"- FHD-909  advancing in Phase 1 trial in SMARCA4  mutated cancers, with non-small cell lung cancer  as the primary target population. - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors supports clinical exploration. - Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models. “We are excited by the preclinical combination data of FHD-909, a first-in-class oral selective SMARCA2 inhibitor, with chemotherapy, KRAS inhibitors and pembrolizumab, which support further clinical exploration in NSCLC,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Building on the robust preclinical monotherapy activity we previously reported, new combination data was presented as part of an oral presentation at this year’s AACR annual meeting. Enrollment and dose escalation continue in the ongoing Phase 1 trial evaluating FHD-909. We look forward to continued progress on our FHD-909","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/foghorn-therapeutics-presents-preclinical-data-200500287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FHTX","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2531266911","title":"CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266911","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266911?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"SINGAPORE, April 28, 2025  -- CytoMed Therapeutics Limited , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates.Net Loss: Excluding costs associated with being a public company listed on the NASDAQ Capital Market amounting to US$188,341, the Company recorded a reduced net loss of US$1.66 million for the financial year ended December 31, 2024. Including these costs, the audited net loss was US$1.85 million, representing a 39% improvement compared to the net loss of US$3.03 million in 2023. The reduction was primarily due to the absence of initial public offerings  related expenses, as well as lower comp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomed-therapeutics-reports-full-ended-200500533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","GDTC","BK4139","LENZ"],"gpt_icon":0},{"id":"2531263564","title":"BriaCell Therapeutics Announces Closing of $13.8 million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2531263564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531263564?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter’s option to purchase additional units. Each unit consists of one common share  and one warrant . Each unit was sold to the public at a price of $4.50 per unit  for gross proceeds of approximately $13.8 million, before deducting underwriting discounts and offering expenses. The Warrants included in the units were approved for listing on the Nasdaq Capital Market and commenced trading under the symbol “BCTXZ” on April 25, 2025. Each Warrant is immediately exercisable, entitles the holder to purchase one common share at an exercise price of $5.25 per share and expires five years from the date of issuance. The Company is r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-closing-13-200500270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTXW","BCTXZ","LENZ","BCTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2531250979","title":"Press Release: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2531250979","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531250979?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:01","pubTimestamp":1745870460,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 28, 2025  -- Spero Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant  bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since November 2023. She will continue to serve as the Company's Chief Financial Officer and Treasurer.Ms. Rajavelu will succeed Spero's previous President and Chief Executive Officer, Sath Shukla. Spero and Mr. Shukla have mutually agreed to separate, effective May 2, 2025, and he will concurrently step down from Spero's Board of Directors. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SPRO","BK4139","BK4007"],"gpt_icon":0},{"id":"2531944254","title":"Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531944254","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531944254?lang=en_us&edition=fundamental","pubTime":"2025-04-29 03:03","pubTimestamp":1745867006,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics  said Friday initial results from a phase 2 trial of NDV-01 for bladder cancer were positive.The study, which was presented at the annual meeting of the American Urology Association, showed that 90% of patients achieved high-grade disease-free status after treatment, supporting NDV-01's potential as a new therapy for non-muscle invasive bladder cancer, the company said.At the three-month mark, 85% of patients responded to treatment, and all patients with carcinoma in situ showed a complete response, it added.At six months, all seven patients who were evaluated remained disease-free, including one who needed a second treatment at three months, according to the company.The drug was generally safe and well-tolerated, with only mild side effects like urinary urgency and slight pain, which resolved within a day, Relmada said.Shares of the company were down over 41% in recent trading.Price: 0.38, Change: -0.27, Percent Change: -41.30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","RLMD","BK4007","BK4139"],"gpt_icon":0},{"id":"2531759255","title":"Relmada Therapeutics Announces Positive Phase 2 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759255?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:47","pubTimestamp":1745862462,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Relmada Therapeutics ( ($RLMD) ). On April 28, 2025, Relmada Therapeutics announced positive initial data from ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relmada-therapeutics-announces-positive-phase-2-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relmada-therapeutics-announces-positive-phase-2-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":13,"totalSize":287,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-05-09","current":-15.25222,"percent":0.091255,"low":-16.900596,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"high":-5.069183,"avg":-10.27698,"sd":3.318099,"marketCap":728141003},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003}],"updateTime":1746875046385}}}